Bepranemab (UCB0107) Disease area studied Abbreviated title Phase Study ID Registry database Study results Plain language summary Publication (if available) Mild Cognitive Impairment or Mild Alzheimer's Disease (AD) A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD) Phase 2 AH0003 Ongoing NCT048676162020-005829-882023-506170-12-00 Barton, M. E. et al. Journal of prevention of Alzheimer's disease 2022; 9 (suppl.1), S55-56 15th Conference Clinical Trials Alzheimer’s Disease (CTAD), November 29-December 2, 2022; San Francisco, USA Progressive Supranuclear Palsy A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy Phase 1 PSP002 Ongoing NCT046581992024-510951-36-00
